Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2015;2015:631-636.
Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129:2836-2846.
Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585-1594.
Bianchi V, Robles R, Alberio L, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100:710-713.
Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One. 2010;5:e10208.
Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4:157-164.
Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost. 2018;3:26-37.
Froissart A, Buffet M, Veyradier A, et al for the French Thrombotic Microangiopathies Reference Center. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104-111.
Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127:3092-3094.
Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug Des Devel Ther. 2019;13:1251-1258.
Cablivi 10 mg powder and solvent for solution for injection. Product Information. European Medicines Agency (EMA). https://www.ema.europa.eu/en/documents/product-information/cablivi-epar-product-information_en.pdf. Published August 2018. Accessed November 20, 2019.
CABLIVI^® (caplacizumab-yhdp) for injection, for intravenous or subcutaneous use. [prescribing information]. Cambridge, MA: Genzyme Corporation; Approved 2019. Revised February 2019..
Peyvandi F, Scully M, Kremer Hovinga JA, et al; Titan Investigators. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511-522.
Scully M, Cataland SR, Peyvandi F, et al for the Hercules Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335-346.
Jestin M, Benhamou Y, Schelpe AS, et al for the French Thrombotic Microangiopathies Reference Center. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132:2143-2153.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University;
Department of Hematology
Saint-Antoine Hospital
Paris, France

Disclosures

Disclosure: Paul Coppo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Octapharma; Roche; Sanofi; Takeda
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Roche; Sanofi; Takeda
Received grants for clinical research from: Alexion Pharmaceuticals, Inc.; Roche

Editors

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Kevan H. Chambers, CBiol, MRSB

Medical Writer, WebMD Global, LLC

Disclosures

Kevan H. Chambers, CBiol, MRSB, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CPD

Fatigue, Bruises, and Thrombocytopenia: What's Your Next Step?

Authors: Paul Coppo, MD, PhD
CPD Released: 1/30/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/30/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, emergency medicine physicians, and nephrologists.

The goal of this activity is to improve clinicians' competence in making appropriate treatment decisions about the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Key clinical data from currently approved therapies for the management of aTTP
Have greater competence related to
- Diagnosing aTTP
- Selecting optimal treatment and treatment duration for acute aTTP based on current clinical evidence

Disclosures

Moderator

Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University;
Department of Hematology
Saint-Antoine Hospital
Paris, France

Disclosures

Disclosure: Paul Coppo, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alexion Pharmaceuticals, Inc.; Octapharma; Roche; Sanofi; Takeda
Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Roche; Sanofi; Takeda
Received grants for clinical research from: Alexion Pharmaceuticals, Inc.; Roche

Editors

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Kevan H. Chambers, CBiol, MRSB

Medical Writer, WebMD Global, LLC

Disclosures

Kevan H. Chambers, CBiol, MRSB, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Fatigue, Bruises, and Thrombocytopenia: What's Your Next Step?

Authors: Paul Coppo, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 1/30/2020

Valid for credit through: 1/30/2021, 11:59 PM EST

processing....

Sous-titres en français

« Return to: Fatigue, Bruises, and Thrombocytopenia: What's Your Next Step?

Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Moderator

Paul Coppo, MD, PhD

Editors

Anne M. Sendaydiego, PharmD

Kevan H. Chambers, CBiol, MRSB

Content Reviewer

Robert Morris, PharmD

CPD

Fatigue, Bruises, and Thrombocytopenia: What's Your Next Step?

Target Audience and Goal Statement

Disclosures

Moderator

Paul Coppo, MD, PhD

Editors

Anne M. Sendaydiego, PharmD

Kevan H. Chambers, CBiol, MRSB

Content Reviewer

Robert Morris, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Fatigue, Bruises, and Thrombocytopenia: What's Your Next Step?

Sous-titres en français